Parkinson’s Disease

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at the MDS International Congress of...

AbbVie Inc (NYSE: ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn...

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting.  The data show that the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase (GCase) protein,...

Prothena Corporation plc (NASDAQ: PRTA) presented new preclinical data from its dual Aβ/tau and tandem C-terminal α-synuclein vaccine programs in Alzheimer's disease (AD) and Parkinson's disease (PD), respectively.  The data were presented at the...

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.  These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD).  The data shows...

The FDA has signed off 4D pharma plc's (NASDAQ: LBPS) investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for Parkinson's disease.  The Company expects to initiate a first-in-human Phase I clinical trial in people with...

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company...

The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ: YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.  The FDA has not halted all clinical programming and permits the Company's planned...

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpoints. YTX-7739 was shown to inhibit its primary target, stearoyl-CoA...

The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's...

Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function. ANVS401 was well-tolerated and safe, with no adverse...

Inhibikase Therapeutics Inc (NASDAQ: IKT) has announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs). The toxicology studies of IkT-148009 include daily oral administration in rats for...

Stealth BioTherapeutics Corp (NASDAQ: MITO) has presented new data from a study evaluating SBT-272 in a murine model of Parkinson's disease (PD).  SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier.  The data were...

The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds, GT-02287 and GT-02329, for Gaucher and GBA1 Parkinson's...

Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations.  Amneal plans to submit a marketing application for IPX-203 with the FDA in mid-2022. The study...